About 500 reports

  • 8.5 RNA INTERFERENCE (GENE SILENCING)
  • RNA ANALYSIS/TRANSCRIPTOMICS RNA INTERFERENCE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

TECHNOLOGY MARKET SHARE (2019) CAGR (2020-2025) Microarrays % % PCR (qPCR) % % Sequencing % % RNA Interference (Gene Silencing) % % Q. ##.

  • Biotech Diagnostics
  • Molecular Diagnostics
  • RNA
  • North America
  • United States
  • Table 11: Gene Silencing (Application) Retrospective Demand
  • Table 12: Gene Silencing (Application) Market Share Breakdown

Gene Silencing Segment to Record ##. ##% CAGR In the global Gene Silencing segment, USA, Canada, Japan, China and Europe will drive the ##% CAGR estimated for this segment.

  • Medical Biotechnology
  • Europe
  • World
  • Demand
  • Transcriptional Gene Silencing
  • TYPES OF GENE SILENCING

Gene silencing is also known as gene knockdown hence when genes are silenced their expression is reduced.

  • Gene Therapy
  • Therapy
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Genzyme Corporation
  • Antisense therapy/gene silencing

gene silencing Active extrusion of bacterial compounds/ membrane pumps Overexpression of Multidrug resistance efflux pumps Siderophores Non-antibiotic Microbial Therapeutics – Therapies Antibodies Lysins Phages Antimicrobial Peptides Defensins Host Directed Therapies Non-anti

  • Anti-Infective
  • Therapy
  • World
  • Competitive Assessment of Late-Stage Pipeline Agents in ATTR, 2019-2029
  • 2.4 RNAI THERAPIES WILL DOMINATE THE ATTR MARKET DURING THE FORECAST PERIOD

The gene silencing pathway is a new mechanism found to be successful in ATTR.

  • Antimalarials
  • Cardiology
  • Endocrine Disease
  • Pathology
  • Pfizer Inc.
  • BBI-801 - DRUG PROFILE

The invention relates to novel compositions for use in silencing K-Ras gene expression.

  • Biopharmaceutical
  • Cancer
  • Pharmaceutical
  • Therapy
  • BioPharma company
  • BBI-801 - DRUG PROFILE

The invention relates to novel compositions for use in silencing K-Ras gene expression.

  • Biopharmaceutical
  • Cancer
  • Pharmaceutical
  • Therapy
  • BioPharma company
  • BBI-801 - DRUG PROFILE

The invention relates to novel compositions for use in silencing K-Ras gene expression.

  • Biopharmaceutical
  • Cancer
  • Pharmaceutical
  • Therapy
  • World
  • phenylbutyrate - Drug Profile

Patients who complete ROMANA ## or ## have the option of continuing treatment in the ROMANA ## safety extension study.

  • Therapy
  • Aoxing Pharmaceutical Company, Inc.
  • Chronos Therapeutics Limited
  • Helsinn Group
  • K-PAX PHARMACEUTICALS, INC.
  • PHENYLBUTYRATE - DRUG PROFILE

Patients were randomly allocated (##:##) to anamorelin hydrochloride ## mg or placebo once-daily for ## weeks.

  • Pharmaceutical
  • Therapy
  • United States
  • World
  • Helsinn Group
  • 4.4.1 Gene Silencing: Gaining Momentum
  • Ltd. - Clinical Pipeline in Gene Therapy

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry’s growth.

  • Clinical Trial
  • Gene Therapy
  • Medical Biotechnology
  • United States
  • World
  • GENE THERAPY TO INHIBIT VEGF-A FOR CORNEAL NEOVASCULARIZATION - DRUG PROFILE

The molecules developed by Companies in Phase III, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Eye Disease
  • Ophthalmology
  • Pathology
  • Therapy
  • EyeGate Pharmaceuticals, Inc.
  • R&D PROGRESS RESEARCH AND DEVELOPMENT BRIEF

The drug candidate inhibits HDACs and increases the accessibility of DNA to the transcriptional machinery, tumor-suppressor genes silenced in diseased cells.

  • Pathology
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • AUSTRALIA: RNAI THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2027 (USD MILLION)
  • AUSTRALIA: RNAI THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2027 (USD MILLION)

These RNAi are used to silence particular genes which are responsible for diseases.

  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • Forecast
  • Market Size
  • 2.4 OLIGONUCLEOTIDES AND COVID-19 PANDEMIC
  • 1.4 OLIGONUCLEOTIDES

The company develops medicines that treat intractable diseases by silencing the genes that cause them.

  • Genomics
  • Therapy
  • World
  • Market Size
  • Alnylam Pharmaceuticals, Inc.
  • JUL 09, 2019: FIRST-IN-CLASS 'GENE-SILENCING' THERAPY APPROVED FOR NHS USE IN ENGLAND TO TREAT HEREDITARY FORM OF AMYLOIDOSIS
  • DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES IN THEIR RESPECTIVE TERRITORIES.

Onpattro remains accused of infringement of Silence European Patent EP ## ## ##B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam' s infringement.

  • Endocrine Disease
  • Hospital
  • Pharmaceutical
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • LARGAZOLE - DRUG PROFILE
  • LARGAZOLE - DRUG PROFILE

Entinostat binds to and inhibits histone deacetylase ## and ##, enzymes that regulates chromatin structure and gene transcription.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Syndax Pharmaceuticals, Inc.
  • Discovery/Preclinical Trial Details

Onpattro remains accused of infringement of Silence European Patent EP ## ## ##B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam' s infringement.

  • Endocrine Disease
  • Neurology
  • Therapy
  • Type 2 Diabetes
  • Alnylam Pharmaceuticals, Inc.
  • development and commercialization activities in their respective territories.

Onpattro remains accused of infringement of Silence European Patent EP ## ## ##B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam' s infringement.

  • Cardiology
  • Endocrine Disease
  • Hospital
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • 6.2 INDUSTRY TRENDS

For instance, only a single type of gene can be analyzed in one run.

  • Biotech Diagnostics
  • Biotechnology
  • Molecular Biology
  • North America
  • United States
  • Gene Silencing
  • INTRODUCTION

Gene Silencing ##. ##. ##.

  • APAC
  • North America
  • United States
  • World
  • Discovery/Preclinical Trial Details
  • R&D Progress Research and Development Brief

The Fas activation leads to apoptosis of the cancer cells and the suppressing of the gene silencing effect.

  • Malaria
  • Therapy
  • United States
  • Product Initiative
  • Epizyme, Inc.
  • 10.15.1 OVERVIEW

PF- ## was developed using Silence Therapeutics' gene silencing RNA, which is known as " AtuRNAi" technology.

  • Eye Disease
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • Type 2 Diabetes
  • Licensing and Collaboration

IT ACTS BY TARGETING BRD## GENE.

  • Cardiovascular Disease
  • Pathology
  • Pharmaceutical
  • Therapy
  • Resverlogix Corp.
  • QPI-1024 - DRUG PROFILE
  • QPLI-1 - DRUG PROFILE

The company concentrates on produced protein structures and avoids general risks associated with gene and cell technologies.

  • General Medicine And Specialty Medicine
  • Lung Transplant
  • Pharmaceutical
  • Therapy
  • Transplantation
  • Discovery/Preclinical Trial Details

Onpattro remains accused of infringement of Silence European Patent EP ## ## ##B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam' s infringement.

  • Endocrine Disease
  • Hospital
  • Neurology
  • Therapy
  • Type 2 Diabetes
  • R&D Progress
  • phenylbutyrate - Drug Profile

Nrf## binds with antioxidant response element (ARE) which induces the expression of the enzyme' s mRNAs of Ho-##, Nqo-##, and Gclm genes thereby decreases light-induced death.

  • Dermatological Condition
  • Pathology
  • Pharmaceutical
  • Therapy
  • Amryt Pharma plc
  • PARTNERSHIPS
  • DEAL IN BRIEF

It target and silence the beta IIItubulin gene.

  • Biopharmaceutical
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Benitec Biopharma Limited
  • EVERFRONT BIOTECH INC
  • DEC 04, 2019: SEELOS THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR AN ADDITIONAL US PATENT FOR TREHALOSE (SLS-005)

In December 2012, University of Iowa filed a patent application (US ##/ ##, ##) entitled " SiRNA-mediated gene silencing. "

  • Dementia
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • Biohaven
  • ORAL MUCOSITIS - PIPELINE BY HUMANETICS CORP, H2 2020
  • GLYCOMIRA THERAPEUTICS INC

The company develops anti-infective products such as anti-bacterial compounds, gene-silencing antivirals, locally delivered and orally available nanoRNA therapeutics.

  • Hospital
  • Pharmaceutical
  • Therapy
  • United States
  • Humanetics Corporation